NewAmsterdam Pharma Company N.V. Basic Shares Outstanding (Weighted Average)
NewAmsterdam Pharma Company N.V. (NAMS) reported Basic Shares Outstanding (Weighted Average) of 123.37 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 123.37M shares, a 4.06% increase year-over-year.
- NewAmsterdam Pharma Company N.V. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 121.72M shares, a 4.81% increase year-over-year.
- NewAmsterdam Pharma Company N.V. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 119.98M shares, a 20.67% increase year-over-year.
- NewAmsterdam Pharma Company N.V. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 119.00M shares, a 25.59% increase year-over-year.
- NewAmsterdam Pharma Company N.V. weighted average number of shares outstanding, basic for fiscal 2025 was 118.42M shares, a 25.51% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. weighted average number of shares outstanding, basic for fiscal 2024 was 94.36M shares, a 14.84% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. weighted average number of shares outstanding, basic for fiscal 2023 was 82.16M shares, a 333.20% increase from fiscal 2022.
- NewAmsterdam Pharma Company N.V. weighted average number of shares outstanding, basic for fiscal 2022 was 18.97M shares, a 72.75% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 123.37M shares 10-Q · filed 2026-08-05 | 122.55M shares 10-Q · filed 2026-08-05 | 121.69M shares derived: average of 3 quarters · filed 2026-08-05 | 121.02M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 121.72M shares 10-Q · filed 2026-05-07 | 120.85M shares derived: average of 2 quarters · filed 2026-05-07 | 120.23M shares derived: average of 3 quarters · filed 2026-05-07 | 119.81M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 119.98M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | 119.49M shares derived: average of 2 quarters · filed 2026-02-18 | 119.18M shares derived: average of 3 quarters · filed 2026-08-05 | 118.42M shares 10-K · filed 2026-02-18 |
| 2025-09-30 | 119.00M shares 10-Q · filed 2025-11-05 | 118.78M shares derived: average of 2 quarters · filed 2026-08-05 | 117.90M shares 10-Q · filed 2025-11-05 | 113.28M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 118.56M shares 10-Q · filed 2026-08-05 | 117.35M shares 10-Q · filed 2026-08-05 | 111.37M shares derived: average of 3 quarters · filed 2026-08-05 | 107.22M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 116.12M shares 10-Q · filed 2026-05-07 | 107.78M shares derived: average of 2 quarters · filed 2026-05-07 | 103.44M shares derived: average of 3 quarters · filed 2026-05-07 | 101.26M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 99.43M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | 97.09M shares derived: average of 2 quarters · filed 2026-02-18 | 96.30M shares derived: average of 3 quarters · filed 2026-02-18 | 94.36M shares 10-K · filed 2026-02-18 |
| 2024-09-30 | 94.75M shares 10-Q · filed 2025-11-05 | 94.73M shares derived: average of 2 quarters · filed 2025-11-05 | 92.67M shares 10-Q · filed 2025-11-05 | 90.08M shares derived: average of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | 94.71M shares 10-Q · filed 2025-08-06 | 91.61M shares 10-Q · filed 2025-08-06 | 88.52M shares derived: average of 3 quarters · filed 2026-02-18 | 87.01M shares derived: average of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | 88.38M shares 10-Q · filed 2025-05-08 | 85.43M shares derived: average of 2 quarters · filed 2026-02-18 | 84.44M shares derived: average of 3 quarters · filed 2026-02-18 | 83.85M shares derived: average of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | 82.47M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | 82.47M shares derived: average of 2 quarters · filed 2026-02-18 | 82.33M shares derived: average of 3 quarters · filed 2026-02-18 | 82.16M shares 10-K · filed 2026-02-18 |
| 2023-09-30 | 82.47M shares 10-Q · filed 2024-11-06 | 82.27M shares derived: average of 2 quarters · filed 2024-11-06 | 82.06M shares 10-Q · filed 2024-11-06 | |
| 2023-06-30 | 82.06M shares 10-Q · filed 2024-08-07 | 81.85M shares 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | 81.63M shares 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 18.97M shares 10-K · filed 2025-02-26 | |||
| 2021-12-31 | 10.98M shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |